Literature DB >> 10963838

Pulmonary delivery of drugs for bone disorders.

J S Patton1.   

Abstract

As the population ages, osteoporosis becomes a growing public health concern. Current treatments provide patients with limited clinical improvement, numerous side effects, and no cure. The naturally-occurring peptides calcitonin and parathyroid hormone, which regulate bone metabolism, offer alternative treatment options. Clinical studies indicate the usefulness of calcitonin and parathyroid hormone in osteoporosis and Paget's disease of bone. For the peptides to become viable therapies, formulations must be developed that bypass the need for injection. Pulmonary delivery of calcitonin and parathyroid hormone appears likely in the near future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963838     DOI: 10.1016/s0169-409x(00)00064-8

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  7 in total

1.  Administration of antibody to the lung protects mice against pneumonic plague.

Authors:  Jim Hill; Jim E Eyles; Stephen J Elvin; Gareth D Healey; Roman A Lukaszewski; Richard W Titball
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Inhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity.

Authors:  Satomi Onoue; Kazuki Kuriyama; Atsushi Uchida; Takahiro Mizumoto; Shizuo Yamada
Journal:  Pharm Res       Date:  2011-02-02       Impact factor: 4.200

3.  The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation.

Authors:  Sunday A Shoyele; Neeraj Sivadas; Sally-Ann Cryan
Journal:  AAPS PharmSciTech       Date:  2011-01-27       Impact factor: 3.246

4.  Pure insulin nanoparticle agglomerates for pulmonary delivery.

Authors:  Mark M Bailey; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  Langmuir       Date:  2008-12-02       Impact factor: 3.882

5.  Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins.

Authors:  Laura J Peek; Lydia Roberts; Cory Berkland
Journal:  Langmuir       Date:  2008-08-05       Impact factor: 3.882

6.  Exploring targeted pulmonary delivery for treatment of lung cancer.

Authors:  Amit Goel; Sanjula Baboota; Jasjeet K Sahni; Javed Ali
Journal:  Int J Pharm Investig       Date:  2013-01

7.  Study of Lysozyme-Loaded Poly-L-Lactide (PLLA) Porous Microparticles in a Compressed CO₂ Antisolvent Process.

Authors:  Yong-Qiang Kang; Chen Zhao; Ai-Zheng Chen; Shi-Bin Wang; Yuan-Gang Liu; Wen-Guo Wu; Xiao-Qian Su
Journal:  Materials (Basel)       Date:  2013-08-19       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.